Butalbital, Acetaminophen, and Caffeine (Page 3 of 3)
Treatment
A single or multiple overdose with this combination product is a potentially lethal polydrug overdose, and consultation with a regional poison control center is recommended.
Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered.
Gastric decontamination with activated charcoal should be administered just prior to N-acetylcysteine (NAC) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation. Serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading. To obtain the best possible outcome, NAC should be administered as soon as possible where impending or evolving liver injury is suspected. Intravenous NAC may be administered when circumstances preclude oral administration.
Vigorous supportive therapy is required in severe intoxication. Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of intoxication.
DOSAGE AND ADMINISTRATION
One or 2 tablets every 4 hours as needed. Total daily dosage should not exceed 6 tablets.
Extended and repeated use of this product is not recommended because of the potential for physical dependence.
HOW SUPPLIED
Butalbital, Acetaminophen, and Caffeine Tablets USP, 50 mg/325mg/40 mg are light-blue, speckled, round uncoated tablets, debossed “1695” on one side and “LCI” on the other side and are supplied in bottles of 20 NDC 68071-3249-
bottles of 30 NDC 68071-3249-3
bottles of 60 NDC 68071-3249-6
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Dispense in a tight container as defined in the USP, with a child-resistant closure (as required).
Distributed by:
Lannett Company, Inc.
Philadelphia, PA 19136
Made in the USA
CIB70307B
Rev. 04/16
PRINCIPAL DISPLAY PANEL
BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE butalbital, acetaminophen, and caffeine tablet | |||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
|
Labeler — NuCare Pharmaceuticals, Inc. (010632300) |
Establishment | |||
Name | Address | ID/FEI | Operations |
NuCre Pharmaceuticals, Inc. | 010632300 | repack (68071-3249) |
Revised: 04/2023 NuCare Pharmaceuticals, Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.
https://medlibrary.org/lib/rx/meds/butalbital-acetaminophen-and-caffeine-57/page/3/